We report a case of tacrolimus-induced transplant-associated thrombotic microangiopathies (TA-TMA) after lung transplantation. A 71-year-old man underwent lung transplantation secondary to idiopathic pulmonary fibrosis. After 4 months, he presented with abdominal discomfort and dyspnea, and was diagnosed with hemolytic anemia and thrombocytopenia. Tacrolimus was considered the cause of the TMA. Tacrolimus was stopped and several sessions of plasma exchange were performed immediately after diagnosis of TA-TMA. However, his platelet count did not normalize, gastrointestinal bleeding was recurrent, and severe pneumonia developed, following which he died. TA-TMA are rare but severe, life-threatening complications in lung transplant recipients. Therefore, the possibility of TA-TMA should be considered in posttransplant recipients.
Aged ; Anemia, Hemolytic ; Diagnosis ; Dyspnea ; Hemorrhage ; Humans ; Idiopathic Pulmonary Fibrosis ; Lung Transplantation* ; Lung* ; Plasma Exchange ; Platelet Count ; Pneumonia ; Tacrolimus ; Thrombocytopenia ; Thrombotic Microangiopathies* ; Transplant Recipients

The active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (calcitriol), inhibits the growth of several types of human cancer cells in vitro, but its therapeutic use is limited because it causes hypercalcemia. Among its analogs, 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol), has fewer calcemic effects and exhibits an activity equipotent to that of calcitriol. We assessed the antitumor and anti-inflammatory effects of paricalcitol in gastric cancer cells, and evaluated the potential role of vitamin D in the treatment of peritoneal metastatic gastric cancer. In this study, treatment with paricalcitol inhibited gastric cancer cell growth and induced cell cycle arrest. Paricalcitol also induced apoptosis and showed anti-inflammatory activity. Moreover, the growth of intraperitoneal metastases in vivo was reduced in mice treated with paricalcitol. 18F-FDG uptake was significantly lower in the paricalcitol group compared to control group (SUV; control group 13.2 +/- 5.3 vs paricalcitol group 4.5 +/- 3.0). Intraperitoneal tumor volume was significantly lower in paricalcitol treated mice (control group 353.2 +/- 22.9 mm3 vs paricalcitol group 252.0 +/- 8.4 mm3). These results suggest that the vitamin D analog, paricalcitol, has anticancer activity on gastric cancer cells by regulation of the cell cycle, apoptosis, and inflammation.
Animals ; Antineoplastic Agents/chemistry/*pharmacology/therapeutic use ; Apoptosis/drug effects ; Cell Cycle Checkpoints/drug effects ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Disease Models, Animal ; Ergocalciferols/chemistry/*pharmacology/therapeutic use ; Fluorodeoxyglucose F18/chemistry/diagnostic use ; Humans ; Mice ; Mice, Inbred BALB C ; Peritoneal Neoplasms/drug therapy/*secondary ; Positron-Emission Tomography ; Stomach Neoplasms/drug therapy/*pathology ; Transplantation, Heterologous

OBJECTIVE: To compare the disability grades previously evaluated and registered, with the re-evaluated ones for individuals with disability living in Seoul. METHOD: Thee hundred and eleven people with disability living in Seoul were selected by the hierarchical systematic extraction method. Their disability grade was re-evaluated in the otolaryngology, ophthalmology, rehabilitation outpatient clinic or via home visit. And the disability level of each person was evaluated by the Korean Activities of Daily Living (K-ADL). RESULTS: Two hundred and twenty nine people with disability were re-evaluated on their disability grades. One hundred and thirty four (58.5%) cases had the same disability grade as initially evaluated. Thirty three cases were re-adjusted to a higher disability grade and sixty two cases to a lower grade. The K-ADL scores of people with brain lesion and spine/spinal cord injury were higher than those of other type of disability, which indicated a higher level of disability. CONCLUSION: When disability grades were re-evaluated, discrepancy rate was 41.5%. For proper management in the process of disability registration, it is imperative to implement a policy, which ensures the re-evaluation of the disability grade at a regular interval, the clear guidelines for grading as well as the competency of the evaluators.
Activities of Daily Living ; Ambulatory Care Facilities ; Brain ; Disabled Persons ; House Calls ; Humans ; Ophthalmology ; Otolaryngology

A 55-year old male presented with chest and abdominal pain for four hours. One day prior to admission he had received chemotherapeutic agents comprising 130 mg cisplatin and 5,200 mg 5-Fluorouracil for nasopharyngeal carcinoma. EKG showed ST elevations in the leads II, III and aVF. The levels of cardiac enzymes were elevated [creatine kinase (CK) 1129 U/L, CK-MB 180 U/L, troponin T 1.23 ng/mL and troponin I 23.29 ng/mL]. Urokinase was administered at the emergency room, but the patient's chest pain continued with persistent ST segment elevations. Urgent coronary and renal angiograms revealed thrombotic occlusive lesions in the distal right coronary and right renal arteries. Percutaneous transluminal renal angioplasty using 6.0x20 mm balloon was performed for the renal artery. However, filling defects and distal renal flow were not improved and so Abciximab (ReoPro(r)) was administered. Follow-up coronary and renal angiograms on the fifth hospital day showed no filling defects with good distal flow in both right coronary and renal arteries.
Abdominal Pain ; Angioplasty ; Chest Pain ; Cisplatin* ; Electrocardiography ; Emergency Service, Hospital ; Fluorouracil* ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Myocardial Infarction ; Phosphotransferases ; Renal Artery* ; Thorax ; Thrombosis* ; Troponin I ; Troponin T ; Urokinase-Type Plasminogen Activator

A 55-year old male presented with chest and abdominal pain for four hours. One day prior to admission he had received chemotherapeutic agents comprising 130 mg cisplatin and 5,200 mg 5-Fluorouracil for nasopharyngeal carcinoma. EKG showed ST elevations in the leads II, III and aVF. The levels of cardiac enzymes were elevated [creatine kinase (CK) 1129 U/L, CK-MB 180 U/L, troponin T 1.23 ng/mL and troponin I 23.29 ng/mL]. Urokinase was administered at the emergency room, but the patient's chest pain continued with persistent ST segment elevations. Urgent coronary and renal angiograms revealed thrombotic occlusive lesions in the distal right coronary and right renal arteries. Percutaneous transluminal renal angioplasty using 6.0x20 mm balloon was performed for the renal artery. However, filling defects and distal renal flow were not improved and so Abciximab (ReoPro(r)) was administered. Follow-up coronary and renal angiograms on the fifth hospital day showed no filling defects with good distal flow in both right coronary and renal arteries.
Abdominal Pain ; Angioplasty ; Chest Pain ; Cisplatin* ; Electrocardiography ; Emergency Service, Hospital ; Fluorouracil* ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Myocardial Infarction ; Phosphotransferases ; Renal Artery* ; Thorax ; Thrombosis* ; Troponin I ; Troponin T ; Urokinase-Type Plasminogen Activator

The familial occurrence of a pituitary adenoma associated with multiple endocrine neoplasia (MEN) type 1 or Carney complex is a well-recognized entity. However, an isolated familial somatotropinoma is a rare inherited disease, which is characterized by clustering of a somatotrophic adenoma and acromegaly or gigantism in a family, but without other manifestations of MEN type 1, with only 68 cases, in 28 families, described in the literature. The mode of inheritance is autosomal dominant, with incomplete penetration, but the genetic background of these pituitary adenomas remains unknown. A family exists where both the father and son were affected. Endocrinological investigations confirmed hypersecretion of GH and IGF-1, and the pituitary adenomas were identified by magnetic resonance image in both cases. There was no symptom of MEN type 1 or other form of endocrine dysfunction. Herein is reported a case of an isolated familial somatotropinoma in Korea, with a review of the literature
Acromegaly ; Adenoma ; Carney Complex ; Fathers ; Gigantism ; Growth Hormone-Secreting Pituitary Adenoma* ; Humans ; Insulin-Like Growth Factor I ; Korea ; Male ; Multiple Endocrine Neoplasia ; Pituitary Neoplasms ; Somatotrophs ; Wills

The familial occurrence of a pituitary adenoma associated with multiple endocrine neoplasia (MEN) type 1 or Carney complex is a well-recognized entity. However, an isolated familial somatotropinoma is a rare inherited disease, which is characterized by clustering of a somatotrophic adenoma and acromegaly or gigantism in a family, but without other manifestations of MEN type 1, with only 68 cases, in 28 families, described in the literature. The mode of inheritance is autosomal dominant, with incomplete penetration, but the genetic background of these pituitary adenomas remains unknown. A family exists where both the father and son were affected. Endocrinological investigations confirmed hypersecretion of GH and IGF-1, and the pituitary adenomas were identified by magnetic resonance image in both cases. There was no symptom of MEN type 1 or other form of endocrine dysfunction. Herein is reported a case of an isolated familial somatotropinoma in Korea, with a review of the literature
Acromegaly ; Adenoma ; Carney Complex ; Fathers ; Gigantism ; Growth Hormone-Secreting Pituitary Adenoma* ; Humans ; Insulin-Like Growth Factor I ; Korea ; Male ; Multiple Endocrine Neoplasia ; Pituitary Neoplasms ; Somatotrophs ; Wills

BACKGROUND: Platelet-activating factor (PAF) induces nuclear factor (NF)-kappaB activation and angiogenesis and increases tumor growth and pulmonary tumor metastasis in vivo. The role of NF-kappaB activation in PAF-induced angiogenesis in a mouse model of Matrigel implantation, and in PAF-mediated pulmonary tumor metastasis were investigated. METHODS: Angiogenesis using Matrigel and experimental pulmonary tumor metastasis were tested in a mouse model. Electrophoretic mobility shift assay was done for the assessment of NF-kappaB translocation to the nucleus. Expression of angiogenic factors, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1alpha, basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) were tested by RT-PCR and ELISA. RESULTS: PAF induced a dose- and time-dependent angiogenic response. PAF-induced angiogenesis was significantly blocked by PAF antagonist, CV6209, and inhibitors of NF-kappaB expression or action, including antisense oligonucleotides to p65 subunit of NF-kappaB (p65 AS) and antioxidants such as alpha-tocopherol and N-acetyl-L-cysteine. In vitro, PAF activated the transcription factor, NF-kappaB and induced mRNA expression of TNF-alpha, IL-1alpha, bFGF, VEGF, and its receptor, KDR. The PAF-induced expression of the above mentioned factors was inhibited by p65 AS or antioxidants. Also, protein synthesis of VEGF was increased by PAF and inhibited by p65 AS or antioxidants. The angiogenic effect of PAF was blocked when anti-VEGF antibodies was treated or antibodies against TNF-alpha, IL-1alpha, and bFGF was co-administrated, but not by antibodies against TNF-alpha, IL-1alpha, and bFGF each alone. PAF-augmented pulmonary tumor metastasis was inhibited by p65 AS or antioxidants. CONCLUSION: These data indicate that PAF increases angiogenesis and pulmonary tumor metastasis through NF-kappaB activation and expression of NF-kappaB-dependent angiogenic factors.
Acetylcysteine ; alpha-Tocopherol ; Angiogenesis Inducing Agents ; Animals ; Antibodies ; Antioxidants ; Electrophoretic Mobility Shift Assay ; Enzyme-Linked Immunosorbent Assay ; Fibroblast Growth Factor 2 ; Interleukins ; Mice ; Neoplasm Metastasis* ; NF-kappa B ; Oligonucleotides, Antisense ; RNA, Messenger ; Transcription Factors ; Tumor Necrosis Factor-alpha ; Vascular Endothelial Growth Factor A

A 28-year old male presented with chest pain of two hours duration. He had histories of 10 years smoking and 2 years of nephrotic syndrome, due to minimal change disease. His EKG showed marked ST segment elevations in the V3-6, I, II, III and aVF leads. The levels of cardiac enzymes were increased (CK: 481 U/l, CK-MB: 96 U/l and Troponin I: 4.8 ng/mL). The prothrombin and activated partial promboplastin times were normal. Accelerated tissue type plasminogen activator (100 mg) was administered at the emergency room, but his chest pain continued, with persistent ST segment elevations. An urgent coronary angiograph revealed huge multiple filling defects, suggestive of thrombi in the proximal left anterior descending artery (LAD), with thrombolysis in the myocardial infarction (TIMI) flow. A rescue percutaneous coronary intervention was performed using repeated angioplasties with a 3.0 mm balloon. However, the filling defects and distal LAD flow did not improve. We administered Abciximab (ReoPro(r)), and the LAD flow improved to a TIMI III flow, with resolution of the thrombus in the LAD. His clinical course was uneventful after discharge, and a left coronary angiogram, at the 6-month follow-up, showed no filling defects, with the TIMI III flow maintained.
Adult ; Angioplasty ; Arteries ; Blood Platelets ; Chest Pain ; Electrocardiography ; Emergency Service, Hospital ; Follow-Up Studies ; Humans ; Male ; Myocardial Infarction* ; Nephrosis, Lipoid ; Nephrotic Syndrome* ; Percutaneous Coronary Intervention ; Prothrombin ; Smoke ; Smoking ; Thrombosis ; Tissue Plasminogen Activator ; Troponin I

BACKGROUND AND OBJECTIVES: Since 1987, coronary stents have changed the pattern of practice of interventional cardiology, by reducing the complications and improving the clinical outcomes. However, coronary stent restenosis still remains a significant clinical problem in the field of interventional cardiology. The aim of this trial was to compare the clinical efficacy of a rotational atherectomy (ROTA), with that of a plain old balloon angioplasty (POBA), in patients with coronary stent restenosis. SUBJECTS AND METHODS: One hundred and three patients (men 80, 58.4+/-10.3 years of age), diagnosed with coronary stent restenosis, at Chonnam National University Hospital, between January 1999 and December 2000, were analyzed. The clinical end-points were the occurrence of major adverse cardiac events (MACE): death, myocardial infarction and target lesion revascularization (TLR) during the one-year clinical follow-up. RESULTS: The baseline clinical and angiographic characteristics were similar between the two groups. Before the percutaneous coronary intervention (PCI), the diameter of stenosis of the POBA and ROTA groups were 81.9+/-14.0 and 82.9+/-10.0%, respectively, which decreased to 25.5+/-15 and 22.7+/-12% after treatment. At the one-year clinical follow-up, the TLR rates were 7.0 and 6.3% in the POBA and ROTA groups, respectively. The MACE results were not different between the two groups (7.0 and 9.4% in the POBA and ROTA groups, respectively). CONCLUSION: There was no significant long-term clinical benefit of a rotational atherectomy prior to a POBA, compared with a POBA alone, for the treatment of coronary stent restenosis.
Angioplasty ; Angioplasty, Balloon* ; Atherectomy, Coronary* ; Cardiology ; Constriction, Pathologic ; Follow-Up Studies* ; Humans ; Jeollanam-do ; Myocardial Infarction ; Percutaneous Coronary Intervention ; Stents*